IL6 and COVID-19: Patients with ischemic heart disease, asthma, and high initial IL-6 and D-dimer levels were associated with a significant increased likelihood of mortality but clinical improvement was associated with a significant reduction in the likelihood of COVID-19 mortality (Table 5).